NANJING, China, May 6 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that the Company is seeking approval to manufacture and sell products containing zanamivir, one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.
GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is the only pharmaceutical company in mainland China that has such a license.
"We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug," commented Mr. Xiaojin Yin, Senior Vice President of Research and Development of Simcere Pharmaceutical Group.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
